Immunate

Human Coagulation Factor VIII and Human von Willebrand Factor, the active ingredient in Immunate, is a coagulation factor replacement therapy presented as a solution for injection for intravenous use. It replaces deficient clotting factors to treat patients with Hemophilia A and von Willebrand disease.

GNH USA supplies Immunate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, conforming to EU standards and intended for use under medical supervision.

Immunate is used in the management of inherited bleeding disorders affecting the clotting cascade.

Hemophilia A: provides factor VIII to achieve hemostasis in patients with factor VIII deficiency. von Willebrand disease: supplies von Willebrand factor to improve platelet adhesion and stabilize factor VIII. Surgical or invasive procedures in affected patients: maintains adequate clotting during the peri‑operative period to prevent excessive bleeding.

Immunate may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions (e.g., chills, fever) - Headache - Nausea - Arthralgia - Mild rash

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Development of inhibitors (neutralizing antibodies) against factor VIII or von Willebrand factor - Thromboembolic events - Disseminated intravascular coagulation (rare)

Prior to initiating Immunate therapy, clinicians should consider the following precautions. - Inhibitor monitoring: assess for development of neutralizing antibodies during treatment. - Allergy assessment: evaluate history of hypersensitivity to plasma‑derived products. - Infection risk: ensure product is stored and handled according to aseptic standards. - Dose adjustment: consider individual patient response and bleeding severity. - Concomitant anticoagulants: use with caution as they may alter hemostatic balance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunate can interact with other medicines that affect coagulation or immune response.

Major Interactions (Avoid): - Other clotting factor concentrates (e.g., recombinant factor VIIa) – may increase thrombosis risk. - High‑dose procoagulant agents – can lead to excessive clot formation.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs) – may reduce efficacy of Immunate. - Antifibrinolytics (tranexamic acid) – may enhance clot stability, requiring monitoring. - Immunosuppressive drugs – may affect inhibitor development.